Global Biopharma Investment and Financing Highlights (March 31 – April 6, 2025)

1. GeneIII Bio-Tec Co., Ltd

• Round and Amount: Pre-A round financing of 100 million yuan, led by JAFCO Asia.

• Technical Direction: Mass production of ergothioneine using synthetic biotechnology for dietary supplements and functional skincare ingredients.

  ---

  
  

2. Yellwin

• Round and Amount: Nearly 100 million yuan in A++ round financing, exclusively invested by Beijing Medical and Health Industry Investment Fund.

• Technical Direction: Development of cardiac surgical implantation and intervention devices, including coronary artery bypass grafting stabilizers, left ventricular assist devices, etc.

  ---

  
  

3. PhageLux

• Round and Amount: Strategic Financing (Amount Not Disclosed), Participated by Anhui Provincial SASAC.

• Technical Direction: Phage Antibacterial Technology, Addressing Drug-Resistant Bacteria in Agriculture and Healthcare.

  ---

  
  

4. ShineyoMedical

• Round and Amount: Tens of millions of yuan in A+++ round financing, invested by Baiyun Financial Holdings.

• Technical Direction: Cardiovascular Minimally Invasive Interventional Devices, including Atrial Fibrillation Pulse Field Ablation Systems and Venous Closure Systems.

  ---

  
  

5. Baojuhe Medical

• Round and Amount: Strategic Financing (Amount Not Disclosed), Participated by Dandelion Ventures and Xindacheng Ventures.

• Technical Direction: Disposable injection pens compatible with pre-filled medications, covering fields such as diabetes and osteoporosis.

  ---

  
  

6. GeneIII Bio-Tec

• Round and Amount: Completed Series C financing (amount undisclosed), investor undisclosed.

• Technical Direction: Research and development of recombinant human collagen and downstream products.

  ---

  
  

7. Dolphin Intelligence

• Round and Amount: Millions of yuan in seed funding, invested by Zhongjing Capital and Echelon Medical.

• Technical Direction: Development of large-scale models in ultrasound medicine to enhance AI's capability in processing ultrasound images.

  ---

  
  

8. Ruishen'an Medical

• Round and Amount: D Round Financing (Amount Not Disclosed), Investor is Rong'an Venture Capital.

• Technical Direction: Implantable neuromodulation devices, such as vagus nerve stimulators.

  ---

  
  

9. Asia Pacific Pharma

• M&A Event: Sale of 100% equity in wholly-owned subsidiary Xingya Pharmaceutical for a total transaction value of 175 million yuan.

• Technical Direction: Production of chemical active pharmaceutical ingredients, transacted by Zhejiang Zhongqingda.

Foreign enterprises

1. Isomorphic Labs (USA)

• Round and Amount: $600 million in Series A financing, led by Thrive Capital, with participation from GV and Alphabet.

• Technical Direction: Development of AI drug design platforms, collaborating with Eli Lilly and Novartis on oncology and immunology drug research and development.

  ---

  
  

2. AIRNA (USA)

• Round and Amount: $155 million in Series B funding, with participation from ARCH Venture Partners, Forbion, and others.

• Technical Direction: RNA Editing Therapy, Advancing the Candidate Drug AIR-001 for Alpha-1 Antitrypsin Deficiency (AATD) into Phase 1/2 Clinical Trials.

  ---

  
  

3. Atsena (USA)

• Round and Amount: $150 million in Series C financing, with participation from Abingworth, Bain Capital, and others.

• Technical Direction: Gene Therapy ATSN-201 for X-linked Retinoschisis (XLRS), Expanding Adenovirus Vector Technology.

  ---

  
  

4. Neurona (USA)

• Round and Amount: Strategic financing of $102 million, with participation from Alexandria Venture Investments, Fidelity, and others.

• Technical Direction: Allogeneic Cell Therapy NRTX-1001, Phase 1/2 Trial for Drug-Resistant Mesial Temporal Lobe Epilepsy (MTLE).

  ---

  
  

5. Prazer (Korea)

• Round and Amount: Series B Financing of 29 billion KRW, with participation from Company K Partners, K2 Investment, and others.

• Technical Direction: Targeted protein degradation technology based on the SPiDEM platform, breaking through the limitations of existing PROTAC technology.

Summary

• Key Focus in China: Synthetic Biology (GeneIII Bio-Tec Co., Ltd), Cardiovascular Devices (Yellwin), AI Medical Equipment (Dolphin Intelligence), and Minimally Invasive Interventions (ShineyoMedical), with API companies (Asia-Pacific Pharmaceuticals) accelerating integration driven by policies.

• International Hotspots: AI Drug Development (Isomorphic Labs), Gene Therapy (Atsena), and RNA Editing (AIRNA) Continue to Lead, while Korea's Prazer Breaks Through in PROTAC Technology.